Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

Summary

The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.

Timeline

Start

2024-09-13

Primary completion

2026-03-31

Completion

2028-09-30

Publications

• Ozaki Y, Koyama S, Morita S, Miyashita M, Tokuda E, Shimoi T, Fukuoka M, Masuda H, Takano Y, Shibata N, Yoshinami T, Murakami A, Tamaki K, Ishiguro H, Saji S, Miwa A, Matsunaga J, Zheng Y, Nishikawa H, Masuda N. Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). BMJ Open. 2026 May 13;16(5):e098088. doi: 10.1136/bmjopen-2024-098088.

Drugs

Indications